We are live on ! Find out more
ZNTL icon

Zentalis Pharmaceuticals
ZNTL

102 hedge funds and large institutions have $102M invested in Zentalis Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 30 increasing their positions, 28 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

604% more call options, than puts

Call options by funds: $971K | Put options by funds: $138K

170% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 10

85% more capital invested

Capital invested by funds: $54.9M → $102M (+$46.8M)

19% more funds holding

Funds holding: 86 → 102 (+16)

5.23% more ownership

Funds ownership: 56.18% → 61.41% (+5.2%)

7% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 28

Holders
102
Holders Change
+16
Holders Change %
+18.6%
% of All Funds
1.26%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
27
Increased
30
Reduced
28
Closed
10
Calls
$971K
Puts
$138K
Net Calls
+$833K
Net Calls Change
+$806K

Top Buyers

1
SCM
Squadron Capital Management
Illinois
+$9.38M
2
Two Sigma Investments
Two Sigma Investments
New York
+$3.84M
3
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$1.6M
4
Millennium Management
Millennium Management
New York
+$1.59M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.45M

Top Sellers

1
Renaissance Technologies
Renaissance Technologies
New York
-$2.44M
2
GCP
GSA Capital Partners
United Kingdom
-$1.42M
3
UBS Group
UBS Group
Switzerland
-$1.34M
4
Morgan Stanley
Morgan Stanley
New York
-$1.17M
5
WP
Woodline Partners
California
-$683K
Name Holding Trade Value Shares
Change 		Change in
Stake
AQR Capital Management
76
AQR Capital Management
Connecticut
$53.1K -$60.2K -23,320 -51%
Universal-Beteiligungs- und Servicegesellschaft
77
Universal-Beteiligungs- und Servicegesellschaft
Germany
$52.5K -$73.9K -28,614 -56%
VGA
78
Vanguard Global Advisers
Pennsylvania
$50.8K +$56.1K +21,725 New
Prudential Financial
79
Prudential Financial
New Jersey
$48.8K -$9.55K -3,700 -15%
SSA
80
Schonfeld Strategic Advisors
New York
$48.2K +$53.2K +20,600 New
PCM
81
Prelude Capital Management
New York
$47.7K +$52.7K +20,400 New
SCP
82
Sivia Capital Partners
California
$46.8K – – –
BC
83
Birchview Capital
Vermont
$41K +$1.3K +503 +3%
ECM
84
Evergreen Capital Management
Washington
$39.6K – – –
CFM
85
Catalyst Funds Management
Australia
$39.1K +$43.1K +16,700 New
CAS
86
CTC Alternative Strategies
Illinois
$29.3K +$32.3K +12,500 New
SC
87
Shay Capital
New York
$24.9K – – –
CWM
88
Cornerstone Wealth Management
Missouri
$23.8K +$26.3K +10,186 New
Carson Wealth (CWM LLC)
89
Carson Wealth (CWM LLC)
Nebraska
$12.6K -$8.23K -3,187 -37%
EWA
90
EverSource Wealth Advisors
Alabama
$3.98K +$142 +55 +3%
Group One Trading
91
Group One Trading
Illinois
$3.42K +$3.77K +1,460 New
TRCT
92
Tower Research Capital (TRC)
New York
$2.65K +$2.93K +1,134 New
WSFS
93
Wilmington Savings Fund Society
Delaware
$2.34K – – –
Nisa Investment Advisors
94
Nisa Investment Advisors
Missouri
$906 – – –
FFO
95
Fortitude Family Office
Arizona
$489 +$540 +209 New
HWM
96
HighMark Wealth Management
Minnesota
$304 – – –
SVCP
97
Silicon Valley Capital Partners
California
$197 +$217 +84 New
Optiver Holding
98
Optiver Holding
Netherlands
$103 – – –
SS
99
SBI Securities
Japan
$63 – – –
II
100
Inspire Investing
Idaho
$50 +$13 +5 +31%
1 2 3
4
5

ZNTL Hedge Fund Activity: Q1 2026 in Review

102 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q1 2026, worth a combined $102M — up 85% from $54.9M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new ZNTL positions and 10 closed out — a net gain of 17 holders — while 30 added to existing stakes and 28 trimmed.

The largest buyer was Squadron Capital Management, opening a new position worth an estimated $9.38M. The largest seller was Renaissance Technologies, cutting an estimated $2.44M.

  • 102 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q1 2026, up from 86 in Q4 2025.
  • Funds reported $102M of Zentalis Pharmaceuticals stock for Q1 2026, up 85% quarter-over-quarter.
  • 27 funds opened new Zentalis Pharmaceuticals positions in Q1 2026 and 10 closed out, a net change of +17 holders.
  • The largest Zentalis Pharmaceuticals buyer in Q1 2026 was Squadron Capital Management, an estimated $9.38M added.
  • The largest Zentalis Pharmaceuticals seller in Q1 2026 was Renaissance Technologies, an estimated $2.44M sold.

Based on aggregated 13F filings for Q1 2026.